Free Trial

Mesoblast (MEOBF) Financials

Mesoblast logo
$1.70 0.00 (0.00%)
As of 05/1/2026
Annual Income Statements for Mesoblast

Annual Income Statements for Mesoblast

This table shows Mesoblast's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.13 -77 -35 -90 -78 -99 -91 -82 -88 -102
Consolidated Net Income / (Loss)
-4.13 -77 -35 -90 -78 -99 -91 -82 -88 -102
Net Income / (Loss) Continuing Operations
-4.13 -77 -35 -90 -78 -99 -91 -82 -88 -102
Total Pre-Tax Income
-91 -90 -66 -99 -87 -100 -92 -82 -88 -102
Total Operating Income
-119 -90 -75 -80 -75 -118 -98 -89 -79 -82
Total Gross Profit
-9.72 -33 -10 -20 -19 -67 -65 -13 -17 -5.77
Total Revenue
-9.72 -33 -10 -20 -19 -56 -48 7.50 5.90 17
Operating Revenue
-9.72 -33 -10 -20 -19 -56 -48 7.50 5.90 17
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 11 17 20 23 23
Operating Cost of Revenue
- 0.00 - - - 11 17 20 23 23
Total Operating Expenses
109 57 65 60 56 51 33 76 62 76
Selling, General & Admin Expense
- - - - - - - 27 25 39
Research & Development Expense
50 59 66 60 56 53 33 53 40 35
Amortization Expense
- - - - - - - 0.00 0.00 5.13
Other Operating Expenses / (Income)
-2.71 -1.49 -1.31 0.33 -0.32 -1.56 0.54 -4.25 -2.57 -3.05
Total Other Income / (Expense), net
28 -0.13 8.71 -18 -13 19 6.81 6.57 -8.91 -20
Other Income / (Expense), net
28 -0.13 8.71 -18 -13 19 6.81 6.57 -8.91 -20
Income Tax Expense
-87 -13 -31 -8.96 -9.42 -0.82 -0.24 -0.21 -0.19 0.33
Basic Earnings per Share
($0.01) ($0.19) ($0.08) ($0.18) ($0.15) ($0.16) ($0.13) ($0.11) ($0.09) ($0.08)
Weighted Average Basic Shares Outstanding
- - 482.64M 498.63M 583.95M 648.70M 650.45M 814.20M 1.14B 1.28B
Diluted Earnings per Share
($0.01) ($0.19) ($0.08) ($0.18) ($0.15) ($0.16) ($0.13) ($0.11) ($0.09) ($0.08)
Weighted Average Diluted Shares Outstanding
- - 482.64M 498.63M 583.95M 648.70M 650.45M 814.20M 1.14B 1.28B
Weighted Average Basic & Diluted Shares Outstanding
- - 482.64M 498.63M 583.95M 648.70M 650.45M 814.20M 1.14B 1.28B

Quarterly Income Statements for Mesoblast

No quarterly income statements for Mesoblast are available.


Annual Cash Flow Statements for Mesoblast

This table details how cash moves in and out of Mesoblast's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents
-28 -35 -7.55 13 77 -113 -76 11 -82 98
Net Cash From Operating Activities
-102 -101 -85 -87 -83 -113 -67 9.96 -74 98
Net Cash From Continuing Operating Activities
-102 -101 -85 -87 -83 -113 -67 9.96 -74 98
Net Income / (Loss) Continuing Operations
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
-102 -101 -85 -87 -83 -113 -67 9.94 -74 98
Changes in Operating Assets and Liabilities, net
- - - - - - - 0.02 - -0.00
Net Cash From Investing Activities
0.00 0.45 0.00 0.00 0.00 0.00 0.00 0.85 -0.27 0.23
Net Cash From Continuing Investing Activities
0.00 0.45 0.00 0.00 0.00 0.00 0.00 0.85 -0.27 0.23
Purchase of Property, Plant & Equipment
- - - - - - - -0.26 -0.27 -0.68
Other Investing Activities, net
0.00 0.45 - - - - - 1.12 - 0.91
Net Cash From Financing Activities
73 60 78 100 163 0.07 -8.83 -0.57 -7.74 -4.00
Net Cash From Continuing Financing Activities
73 65 78 100 163 0.07 -8.83 -0.57 -7.74 -4.00
Repayment of Debt
0.00 0.00 -0.39 -1.61 -0.51 - -61 -0.57 -12 -9.17
Other Financing Activities, net
4.47 3.31 6.17 27 18 0.07 0.02 0.00 3.82 5.18
Cash Interest Received
1.13 0.48 0.37 0.73 0.55 0.02 0.01 0.80 1.78 3.55

Quarterly Cash Flow Statements for Mesoblast

No quarterly cash flow statements for Mesoblast are available.


Annual Balance Sheets for Mesoblast

This table presents Mesoblast's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets
656 692 652 734 745 662 669 669 785
Total Current Assets
64 101 63 137 148 70 82 86 204
Cash & Equivalents
46 38 50 129 137 60 71 63 162
Accounts Receivable
3.74 50 4.06 1.57 4.84 4.40 7.00 21 15
Inventories, net
- - - - - - - 0.00 22
Prepaid Expenses
14 13 8.04 5.65 6.50 4.99 3.34 2.55 5.69
Plant, Property, & Equipment, net
1.81 1.08 0.83 2.29 3.02 2.05 1.36 1.11 1.70
Plant, Property & Equipment, gross
1.81 1.08 0.83 2.29 3.02 2.05 1.36 1.11 1.70
Total Noncurrent Assets
590 590 589 595 593 590 586 582 579
Intangible Assets
586 585 583 582 581 579 577 576 572
Other Noncurrent Operating Assets
1.92 5.68 5.64 13 13 12 9.22 5.85 6.81
Total Liabilities & Shareholders' Equity
656 692 652 731 742 657 661 606 745
Total Liabilities
139 146 171 184 163 165 168 189 187
Total Current Liabilities
37 24 44 90 94 51 42 73 103
Short-Term Debt
- 0.00 14 32 53 5.02 5.95 14 54
Accounts Payable
22 19 13 25 20 23 20 7.07 19
Other Current Liabilities
15 5.08 7.26 33 21 21 10 2.63 2.68
Total Noncurrent Liabilities
102 122 127 94 69 114 126 116 85
Long-Term Debt
0.00 59 67 57 41 92 103 100 68
Capital Lease Obligations
- - 0.00 6.32 8.49 7.09 3.67 1.95 3.58
Total Equity & Noncontrolling Interests
517 546 481 549 581 497 502 480 597
Total Preferred & Common Equity
517 546 481 549 581 497 502 480 597
Total Common Equity
517 546 481 549 581 497 502 480 597
Common Stock
830 889 910 1,051 1,163 1,165 1,249 1,311 1,509
Retained Earnings
-345 -380 -470 -549 -648 -739 -821 -909 -1,011
Other Equity Adjustments
31 37 41 47 66 71 74 78 99

Quarterly Balance Sheets for Mesoblast

No quarterly balance sheets for Mesoblast are available.


Annual Metrics And Ratios for Mesoblast

This table displays calculated financial ratios and metrics derived from Mesoblast's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% -236.18% 69.15% -101.12% 7.40% -199.29% 14.95% 4.50% 26.67% 191.39%
EBITDA Growth
0.00% 0.67% 26.87% -49.68% 11.54% -14.05% 8.07% 10.36% -7.36% -9.68%
EBIT Growth
0.00% 0.67% 26.87% -49.68% 11.54% -14.05% 8.07% 10.36% -7.36% -15.50%
NOPAT Growth
0.00% 24.26% 17.09% -7.66% 7.19% -58.55% 16.84% 9.89% 10.64% -3.45%
Net Income Growth
0.00% -1,761.28% 54.06% -154.46% 13.21% -26.78% 7.55% 10.35% -7.41% -16.13%
EPS Growth
0.00% -1,603.54% 60.62% -139.58% 18.83% -10.79% 7.55% 10.35% 15.38% 5.05%
Operating Cash Flow Growth
0.00% 1.11% 15.51% -2.30% 5.50% -36.73% 40.25% -17.13% 14.19% 231.30%
Free Cash Flow Firm Growth
0.00% 0.00% 71.64% 99.63% -10,424.09% -94.94% 43.88% -5.95% 33.15% 38.42%
Invested Capital Growth
0.00% 0.00% 21.03% -9.82% 1.25% 6.07% -0.86% 1.08% -1.82% 0.82%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.55%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -562.17%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -476.58%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -592.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -593.92%
Tax Burden Percent
4.54% 85.15% 53.49% 90.93% 89.22% 99.18% 99.74% 99.74% 99.78% 100.32%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.58%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -84.15%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.37%
Return on Equity (ROE)
0.00% -14.86% -6.64% -17.49% -15.13% -17.48% -16.94% -16.40% -17.91% -18.95%
Cash Return on Invested Capital (CROIC)
0.00% -226.89% -29.12% -0.10% -11.38% -21.40% -11.72% -12.40% -8.32% -10.39%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14.01%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14.05%
Return on Common Equity (ROCE)
0.00% -14.86% -6.64% -17.49% -15.13% -17.48% -16.94% -16.40% -17.91% -18.95%
Return on Equity Simple (ROE_SIMPLE)
0.00% -14.86% -6.46% -18.67% -14.19% -17.00% -18.38% -16.32% -18.31% 0.00%
Net Operating Profit after Tax (NOPAT)
-83 -63 -52 -56 -52 -83 -69 -62 -55 -57
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -333.61%
Net Nonoperating Expense Percent (NNEP)
0.00% -57.61% 130.09% 127.68% -29,713.06% -51.01% 275.61% 40.87% 59.33% 74.57%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - - -7.94%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 133.55%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 228.57%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 202.39%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 443.03%
Earnings before Interest and Taxes (EBIT)
-91 -90 -66 -99 -87 -100 -92 -82 -88 -102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-91 -90 -66 -99 -87 -100 -92 -82 -88 -97
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 1.07 2.07 1.50 0.58 1.01 0.29 4.16
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 1,026.54 0.00 0.00 0.00 97.08
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 144.60
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 1.06 2.13 1.53 0.61 1.00 0.35 4.08
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 142.50
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 25.08
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.11 0.17 0.17 0.18 0.21 0.22 0.24 0.21
Long-Term Debt to Equity
0.00 0.00 0.11 0.14 0.12 0.09 0.20 0.21 0.21 0.12
Financial Leverage
0.00 -0.09 -0.02 0.05 0.00 -0.06 0.02 0.10 0.11 0.11
Leverage Ratio
0.00 1.27 1.27 1.31 1.34 1.31 1.30 1.33 1.36 1.35
Compound Leverage Factor
0.00 1.27 1.27 1.31 1.34 1.31 1.30 1.33 1.36 1.35
Debt to Total Capital
0.00% 0.00% 9.81% 14.46% 14.85% 15.02% 17.26% 18.30% 19.49% 17.36%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 2.49% 5.03% 7.78% 0.84% 0.97% 2.32% 7.49%
Long-Term Debt to Total Capital
0.00% 0.00% 9.81% 11.96% 9.82% 7.24% 16.43% 17.33% 17.17% 9.87%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 100.00% 90.19% 85.55% 85.15% 84.98% 82.74% 81.70% 80.51% 82.64%
Debt to EBITDA
0.00 0.00 -0.90 -0.82 -1.10 -1.03 -1.13 -1.37 -1.32 -1.30
Net Debt to EBITDA
0.00 0.00 -0.33 -0.31 0.38 0.34 -0.47 -0.50 -0.61 0.37
Long-Term Debt to EBITDA
0.00 0.00 -0.90 -0.68 -0.73 -0.50 -1.08 -1.30 -1.16 -0.74
Debt to NOPAT
0.00 0.00 -1.14 -1.44 -1.83 -1.24 -1.51 -1.81 -2.10 -2.19
Net Debt to NOPAT
0.00 0.00 -0.41 -0.55 0.64 0.41 -0.63 -0.66 -0.96 0.63
Long-Term Debt to NOPAT
0.00 0.00 -1.14 -1.20 -1.21 -0.60 -1.43 -1.72 -1.85 -1.24
Altman Z-Score
0.00 0.00 0.00 0.29 2.31 1.56 -1.01 -0.30 -1.92 5.91
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
0.00 1.73 4.21 1.41 1.51 1.57 1.36 1.95 1.18 1.99
Quick Ratio
0.00 1.35 3.67 1.23 1.45 1.50 1.26 1.87 1.15 1.72
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -532 -151 -0.56 -59 -114 -64 -68 -45 -62
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 14,371.03%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.96
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.25
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.48 0.81 0.93 1.69 1.76
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 380.09
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 759.20 450.52 392.03 215.86 207.80
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 172.29
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
0.00 469 568 512 518 550 545 551 541 601
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03
Increase / (Decrease) in Invested Capital
0.00 469 99 -56 6.38 31 -4.75 5.88 -10 4.87
Enterprise Value (EV)
0.00 0.00 0.00 543 1,102 839 331 550 192 2,451
Market Capitalization
0.00 0.00 0.00 513 1,136 874 288 509 139 2,487
Book Value per Share
$0.00 $0.00 $1.13 $1.00 $1.10 $1.00 $0.77 $0.77 $0.59 $0.52
Tangible Book Value per Share
$0.00 $0.00 ($0.08) ($0.21) ($0.06) $0.00 ($0.13) ($0.12) ($0.12) $0.02
Total Capital
0.00 517 605 562 645 684 601 614 597 723
Total Debt
0.00 0.00 59 81 96 103 104 112 116 125
Total Long-Term Debt
0.00 0.00 59 67 63 50 99 106 102 71
Net Debt
0.00 -46 22 31 -34 -34 43 41 53 -36
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -19 39 -18 -50 -30 -37 -26 -36 -5.67
Debt-free Net Working Capital (DFNWC)
0.00 27 77 32 79 107 23 46 27 156
Net Working Capital (NWC)
0.00 27 77 18 46 54 18 40 13 102
Net Nonoperating Expense (NNE)
-79 14 -17 34 26 16 22 20 32 45
Net Nonoperating Obligations (NNO)
0.00 -48 22 31 -31 -32 48 49 60 3.93
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.13
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32.98%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 906.38%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 591.49%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($0.61) ($1.45) ($1.18) ($1.31) $0.00 ($0.89) ($0.09) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 60.33M 62.33M 72.99M 81.09M 0.00 101.78M 1.14B 1.28B
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($0.61) ($1.45) ($1.18) ($1.31) ($1.13) ($0.89) ($0.09) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 60.33M 62.33M 72.99M 81.09M 81.31M 101.78M 1.14B 1.28B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($0.61) ($1.45) ($1.18) ($1.31) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 60.33M 62.33M 72.99M 81.09M 81.31M 101.78M 1.14B 1.28B
Normalized Net Operating Profit after Tax (NOPAT)
-40 -63 -52 -56 -52 -83 -69 -62 -55 -57
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -333.61%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -592.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Mesoblast

No quarterly metrics and ratios for Mesoblast are available.



Financials Breakdown Chart

Frequently Asked Questions About Mesoblast's Financials

When does Mesoblast's financial year end?

According to the most recent income statement we have on file, Mesoblast's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

How has Mesoblast's net income changed over the last 9 years?

Mesoblast's net income appears to be on an upward trend, with a most recent value of -$102.14 million in 2025, rising from -$4.13 million in 2016. The previous period was -$87.96 million in 2024.

What is Mesoblast's operating income?
Mesoblast's total operating income in 2025 was -$81.96 million, based on the following breakdown:
  • Total Gross Profit: -$5.77 million
  • Total Operating Expenses: $76.19 million
How has Mesoblast's revenue changed over the last 9 years?

Over the last 9 years, Mesoblast's total revenue changed from -$9.72 million in 2016 to $17.20 million in 2025, a change of -277.0%.

How much debt does Mesoblast have?

Mesoblast's total liabilities were at $187.24 million at the end of 2025, a 0.8% decrease from 2024, and a 34.8% increase since 2017.

How much cash does Mesoblast have?

In the past 8 years, Mesoblast's cash and equivalents has ranged from $37.76 million in 2018 to $161.55 million in 2025, and is currently $161.55 million as of their latest financial filing in 2025.

How has Mesoblast's book value per share changed over the last 9 years?

Over the last 9 years, Mesoblast's book value per share changed from 0.00 in 2016 to 0.52 in 2025, a change of 52.3%.



Financial statements for OTCMKTS:MEOBF last updated on 11/24/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners